Hailshadow Shares of BioLineRx ( NASDAQ: BLRX ) jumped 14% Friday after the company announced that St. Jude Children’s Research Hospital will be sponsoring a Phase 1 clinical trial of its drug motixafortide in the treatment of sickle cell disease, or SCD. BioLineRx said the trial will evaluate the drug for the mobilization of CD34+ hematopoietic stem cells used in the development of gene therapies for SCD.
The company noted that genetically modified hematopoietic stem cells are a potential curative treatment for the genetic disease. Motixafortide, also known as Aphexda, was approved by the FDA in 2023 for use with filgrastim in the mobilization of hematopoietic stem cells for collection and autologous transplantation in patients with multiple myeloma. In December 2023, the FDA approved two gene therapies for the treatment of SCD, Vertex Pharmaceuticals ( VRTX ) and CRISPR Therapeutics’ ( CRSP ) Casgevy and bluebird bio’s ( BLUE ) Lyfgenia.
More on BioLineRx BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on BioLineRx Historical earnings data for BioLineRx Financial information for BioLineRx.
